NCT01749228

Bioequivalence Study of Etodolac Capsules USP 300 mg Under Fed Condition

An Open Label, Balanced, Randomized, Single-dose, Two-treatment, Two-sequence, Two-period, Crossover, Oral Bioequivalence Study of Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India and Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA in Healthy, Adult, Human Subjects Under Fed Condition.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: IPCA Laboratories Ltd. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

This is a open Label, balanced, randomized, single dose, two-treatment, two-sequence, two-period, crossover pivotal study. The purpose of this study is to assess the bioequivalence between Test Product and the corresponding Reference Product under fed condition in healthy, adult human subjects.

Detailed description

Objective of this pivotal study was to assess the bioequivalence between Test Product: Etodolac Capsules USP 300 mg of Ipca Laboratories Limited, India and the corresponding Reference Product: Etodolac Capsules USP 300mg of Taro Pharmaceutical Industries Ltd., USA, under fed condition in healthy, adult, human subjects in a randomized crossover study. The study was conducted with 36 healthy adult subjects. In each study period, a single 300 mg dose of either test or reference was administered to the subjects as per the randomization schedule in each study period with about 240 mL of water at ambient temperature in sitting position. The duration of the clinical phase was approximately 10 days including washout period of 7 days between administrations of study drug in each study period.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Etodolac Capsules USP 300 mg	300 mg capsule once a day
DRUG	Etodolac	500 mg tablet once a day

Timeline

• Start date: 2012-10-01
• Primary completion: 2012-12-01
• Completion: 2012-12-01
• First posted: 2012-12-13
• Last updated: 2012-12-13

Locations

1 site across 1 country: India